US › Healthcare

NervGen Pharma Corp. (NGEN)

US · Healthcare · Biotechnology

$2.27+6.57%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-30.0M

EPS

$-0.37

EPS estimate

$-0.09

EPS came in at -0.37 against a street estimate of -0.09 — a miss of 311.1%.

Key statistics

Market cap

$229.0M

Forward P/E

0.0

P/B

18.47

Book value

$0.12

EPS (TTM)

$-0.57

52-week high

$6.30

52-week low

$1.58

50-day MA

$1.88

200-day MA

$3.36

Beta

0.73

Analyst view

with an average price target of $10.00.

Shareholding

Insiders

15.56%

Institutions

11.16%

Largest institutional holders

Fund	Stake
Empery Asset Management, LP	3.72%
Rock Springs Capital Management LP	1.12%
PFG Investments, LLC	0.20%
Bank of America Corp	0.19%
Marshall Wace Asset Management Ltd	0.19%
Royal Bank of Canada	0.16%
Quadrature Capital Limited	0.13%
Integrated Wealth Concepts LLC	0.08%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for NervGen Pharma Corp. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.